159 related articles for article (PubMed ID: 27668043)
1. Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.
Helwick C
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):36-9. PubMed ID: 27668043
[No Abstract] [Full Text] [Related]
2. Food and Drug Administration approvals in phase 3 Cancer clinical trials.
Abi Jaoude J; Kouzy R; Ghabach M; Patel R; Pasalic D; Ghossain E; Miller AB; Lin TA; Verma V; Fuller CD; Subbiah V; Minsky BD; Ludmir EB; Taniguchi CM
BMC Cancer; 2021 Jun; 21(1):695. PubMed ID: 34118915
[TBL] [Abstract][Full Text] [Related]
3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
4. Approvals Expand Multiple Myeloma Treatment Options.
Cancer Discov; 2021 Jun; 11(6):OF5. PubMed ID: 33906862
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Joseph NS; Tai YT; Anderson KC; Lonial S
Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
7. Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.
Yu T; Hsu YJ; Fain KM; Boyd CM; Holbrook JT; Puhan MA
BMJ Open; 2015 Nov; 5(11):e007960. PubMed ID: 26614616
[TBL] [Abstract][Full Text] [Related]
8. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
Elbaz J; Haslam A; Prasad V
Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
[TBL] [Abstract][Full Text] [Related]
9. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?
Cherny NI
Nat Rev Clin Oncol; 2022 Jul; 19(7):486-492. PubMed ID: 35484286
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Hasanali ZS; Razzo B; Susanibar-Adaniya SP; Garfall AL; Stadtmauer EA; Cohen AD
Hematol Oncol Clin North Am; 2024 Apr; 38(2):383-406. PubMed ID: 38158242
[TBL] [Abstract][Full Text] [Related]
11. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
Kim MS; Xu A; Haslam A; Prasad V
Int J Cancer; 2022 Jun; 150(11):1905-1910. PubMed ID: 35182072
[TBL] [Abstract][Full Text] [Related]
12. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
13. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
14. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
Leo CP; Hentschel B; Szucs TD; Leo C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
[TBL] [Abstract][Full Text] [Related]
15. Integration of Novel Agents into the Care of Patients with Multiple Myeloma.
Orlowski RZ; Lonial S
Clin Cancer Res; 2016 Nov; 22(22):5443-5452. PubMed ID: 28151712
[TBL] [Abstract][Full Text] [Related]
16. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
Kazandjian D; Landgren O
Semin Oncol; 2016 Dec; 43(6):682-689. PubMed ID: 28061986
[TBL] [Abstract][Full Text] [Related]
17. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
Hilal T; Gonzalez-Velez M; Prasad V
JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant end points and new drug approvals for myeloma.
Anderson KC; Kyle RA; Rajkumar SV; Stewart AK; Weber D; Richardson P;
Leukemia; 2008 Feb; 22(2):231-9. PubMed ID: 17972944
[TBL] [Abstract][Full Text] [Related]
19. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
